Korean J Hepatol.  2007 Mar;13(1):9-19.

Hypoxia in Hepatocellular Carcinoma

Affiliations
  • 1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. yoonjh@snu.ac.kr

Abstract

Hepatocellular carcinoma (HCC) is characterized by hypervascularity, indicating that angiogenesis plays a vital role in HCC growth and progression. A number of anti-angiogenic therapies are being utilized in clinical trials in patients with HCC. However, the therapeutic efficacy of anti-angiogenic monotherapy is still insufficient. While inhibition of angiogenesis results in tumor hypoxia and cell death, this inhibition may also activate hypoxia-induced cell signals that may promote HCC progression. Therefore, an understanding of these signals may be essential in designing efficient anti-angiogenic therapies. This review summarizes the role of hypoxia-induced signals in HCC.

Keyword

Carcinoma, hepatocellular; Angiogenesis inducing agent; Angiogenesis inhibitors; Hypoxia

MeSH Terms

Angiogenesis Inhibitors/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Cell Hypoxia
Disease Progression
Humans
Liver Neoplasms/*drug therapy
Full Text Links
  • KJHEP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr